| REGEN BIOPHARMA, INC. (OTC: RGBP: $0.009) | |
| Industry: BioPharma | Price Target: $0.30 |
Price as of 12/3/25 |
$0.009 |
52 Week High – Low |
$0.1273 – $0.0079 |
Est. Common Shares Out |
108.3M |
Market Capitalization |
$1M |
Average Volume |
1,152,670 |
Exchange |
OTCID |
Information
4700 Spring Street
Suite 304
La Mesa CA 91942
Web: www.RegenBiopharmaInc.com
Email: david.koos@regenbiopharma.com
Phone: 619.722.5505
In early December, savvy investors routinely focus on stocks primed to make a major jump in the early part of the new year In our view, Regen is the perfect candidate to fit that bill. Biopharma stocks tend to make huge moves to the upside ahead of or based on developmental news and Regen is on track to launch a Phase I clinical trial for its lead candidate in early 1Q26.
The Company’s peer group has already started to make its move, and we believe Regen is set to move right behind it. Despite the market’s volatility, Regen’s peers have risen by roughly 10% in just the past 3 weeks.
HemaXellerate, is an innovative stem cell-derived therapy with a $1 billion potential market opportunity. This lead candidate’s primary indication is to treat chemotherapy patients who have developed a potentially terminal side effect, severe aplastic anemia. There is only one FDA-approved therapy and it carries a hefty price tag and a poor side effect profile.
Regen could be awarded an Orphan Drug Designation for this product, which would be a major coup for the Company.Regen is also evaluating expanded applications for this groundbreaking therapy.
We reiterate our price target of $0.30 which reflects a meaningful discount to the valuation enjoyed by its Phase I peer group. Looking ahead, we believe HemaXellerate could be an attractive acquisition target for opportunistic acquirers.
Table I. Regen Phase I Trial Peer Group |
||||||
|---|---|---|---|---|---|---|
Company Name |
Symbol |
Price (11/3/25) |
Mkt Cap (mil) |
Phase I Candidates |
Preclinical Candidates |
Details |
| Palisade Bio | PALI | $2.11 | $317 | 2 | 3 | Two current Phase I candidates |
| Curanex | CURX | $0.50 | $15 | 0 | 1 | Six indications for single compound |
| Satellos | MSCLF | $0.52 | $94 | 1 | 1 | Phase 1 Completed |
| Average | $142 | |||||
| Regen-Today | RGBP | $0.011 | $1.2 | |||
| Regen-Phase I | $0.30 | $30 | ||||
Sources: www.Yahoo!Finance.com, Company websites, GSCR
Rob Goldman founded Goldman Small Cap Research in 2009 and has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray’s Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.’s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.
ANALYST CERTIFICATION
I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.
This Opportunity Research report was prepared for informational purposes only.
Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select format reflects the irm’s internally generated stock ideas along with economic and stock market outlooks. Opportunity Research reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored micro-cap research ideas that typically carry greater risks than those stocks covered in the Select Research category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Research reports on profiled stocks in the Opportunity Research format typically have a higher risk profile and may offer greater upside. During 2023, Goldman Small Cap Research was compensated by a third party in the amount of $5000 for research reports and a press release. In July 2025, Goldman Small Cap Research was compensated $5000 for a research report and a press release. In July 2025, Goldman Small Cap Research was not compensated for a follow-on research update. In August and September 2025, Goldman Small Cap Research was compensated $21,000 for research content production and content distribution. In October 2025, Goldman Small Cap Research was compensated $500 for research content production. In November 2025, Goldman Small Cap Research was compensated $5800 for research content production and distribution.
All information contained in this report was provided by the Company via filings, press releases or its website, or through our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations
Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own and are made in reliance upon our rights under the First Amendment to the U.S. Constitution and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Such information and the opinions expressed are subject to change without notice.
Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This report does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority
BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION
For more information, visit our Disclaimer: www.goldmanresearch.com